{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:57:18Z","timestamp":1788195438785,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The South China Center for Innovative Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>AD16 is a Class 1.1 new drug candidate for Alzheimer\u2019s disease (AD), which has demonstrated potential benefits in AD by reducing neuroinflammation in preclinical studies. Herein, the pharmacokinetics (PK), safety, and tolerability of single and multiple-dose AD16 and the effect of food were assessed in healthy Chinese adults.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Single-center, randomized, placebo-controlled, double-blind studies were conducted for single and multiple ascending doses. A total of 62 subjects were enrolled in single-dose groups; 10 each in 5, 10, 20, 30, and 40\u00a0mg groups, and 6 each in 60 and 80\u00a0mg dose groups. Twenty subjects were divided equally into 30 and 40\u00a0mg groups for the multiple-dose study. To determine the effect of a high-fat diet on AD16, 16 subjects were administered a single 20\u00a0mg dose of AD16 under the fasted and fed condition in a single-center, randomized, open-label, two-cycle, two-crossover study. Moreover, safety and PK parameters were also assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Plasma exposure to a single oral dose of AD16 increased at an approximate dose-increasing rate. The pharmacodynamic dose of the AD16 can be maintained through the accumulation effect of the drug within the safety window. Compared to fasting, ingesting a high-fat meal decelerated the rate of AD16 absorption, albeit without effect on its overall absorption. No dose-related toxicities were seen in any of the studies, all treatment-emergent adverse events were grade I\/II, and no serious adverse event occurred.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present study exhibited favorable safety, tolerability, and PK profile of AD16, supporting its further research as a potential drug treatment for AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov; NCT05787028, NCT05787041, NCT05806177. The SAD and FE studies were retrospectively registered on 28 March 2023. The MAD study was retrospectively registered on 10 April 2023.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-023-03126-9","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T10:02:41Z","timestamp":1700733761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer\u2019s disease: a randomized phase 1 study"],"prefix":"10.1186","volume":"21","author":[{"given":"Daizhuang","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengmei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"3126_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/bs.irn.2020.03.022","volume":"154","author":"G Plascencia-Villa","year":"2020","unstructured":"Plascencia-Villa G, Perry G. Status and future directions of clinical trials in Alzheimer\u2019s disease. Int Rev Neurobiol. 2020;154:3\u201350.","journal-title":"Int Rev Neurobiol"},{"key":"3126_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/joim.12843","volume":"285","author":"A Calder\u00f3n-Larra\u00f1aga","year":"2019","unstructured":"Calder\u00f3n-Larra\u00f1aga A, Vetrano DL, Ferrucci L, Mercer SW, Marengoni A, Onder G, Eriksdotter M, Fratiglioni L. Multimorbidity and functional impairment-bidirectional interplay, synergistic effects and common pathways. J Intern Med. 2019;285:255\u201371.","journal-title":"J Intern Med"},{"issue":"15","key":"3126_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","volume":"2019","author":"Alzheimer\u2019s Association.","year":"2019","unstructured":"Alzheimer\u2019s Association. Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2019;2019(15):321\u201387.","journal-title":"Alzheimers Dement"},{"key":"3126_CR4","doi-asserted-by":"publisher","first-page":"937486","DOI":"10.3389\/fnagi.2022.937486","volume":"14","author":"X Li","year":"2022","unstructured":"Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132019. Front Aging Neurosci. 2022;14:937486.","journal-title":"Front Aging Neurosci"},{"key":"3126_CR5","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1248\/cpb.c19-00511","volume":"67","author":"G Tezel","year":"2019","unstructured":"Tezel G, Timur SS, Bozkurt \u0130, T\u00fcrko\u011flu \u00d6F, Ero\u011flu \u0130, Nemutlu E, \u00d6ner L, Ero\u011flu H. A snapshot on the current status of Alzheimer\u2019s disease, treatment perspectives, in-vitro and in-vivo research studies and future opportunities. Chem Pharm Bull (Tokyo). 2019;67:1030\u201341.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"3126_CR6","doi-asserted-by":"publisher","first-page":"113320","DOI":"10.1016\/j.ejmech.2021.113320","volume":"216","author":"S Srivastava","year":"2021","unstructured":"Srivastava S, Ahmad R, Khare SK. Alzheimer\u2019s disease and its treatment by different approaches: a review. Eur J Med Chem. 2021;216:113320.","journal-title":"Eur J Med Chem"},{"key":"3126_CR7","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1093\/brain\/awv199","volume":"138","author":"JB Toledo","year":"2015","unstructured":"Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argil\u00e9s JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ, Alzheimer\u2019s Disease Neuroimaging Initiative. Alzheimer\u2019s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain. 2015;138:2701\u201315.","journal-title":"Brain."},{"key":"3126_CR8","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.3233\/JAD-179932","volume":"64","author":"H Hampel","year":"2018","unstructured":"Hampel H, Toschi N, Babiloni C, Baldacci F, Black KL, Bokde ALW, Bun RS, Cacciola F, Cavedo E, Chiesa PA, Colliot O, Coman CM, Dubois B, Duggento A, Durrleman S, Ferretti MT, George N, Genthon R, Habert MO, Herholz K, Koronyo Y, Koronyo-Hamaoui M, Lamari F, Langevin T, Leh\u00e9ricy S, Lorenceau J, Neri C, Nistic\u00f2 R, Nyasse-Messene F, Ritchie C, Rossi S, Santarnecchi E, Sporns O, Verdooner SR, Vergallo A, Villain N, Younesi E, Garaci F, Lista S, Alzheimer Precision Medicine Initiative (APMI). Revolution of Alzheimer precision neurology Passageway of systems biology and neurophysiology. J Alzheimers Dis. 2018;64:S47\u2013105.","journal-title":"J Alzheimers Dis."},{"key":"3126_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, O\u2019Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367.","journal-title":"Brain"},{"key":"3126_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jalz.2014.11.001","volume":"11","author":"MW Weiner","year":"2015","unstructured":"Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, Shen L, Schwarz A, Toga AW, Trojanowski JQ, Alzheimer\u2019s Disease Neuroimaging Initiative. 2014 Update of the Alzheimer\u2019s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2015;11:e1-120.","journal-title":"Alzheimers Dement."},{"key":"3126_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/B978-0-12-804766-8.00013-3","volume":"167","author":"JA Soria Lopez","year":"2019","unstructured":"Soria Lopez JA, Gonz\u00e1lez HM, L\u00e9ger GC. Alzheimer\u2019s disease. Handb Clin Neurol. 2019;167:231\u201355.","journal-title":"Handb Clin Neurol"},{"key":"3126_CR12","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388:2873\u201384.","journal-title":"Lancet"},{"key":"3126_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378:321\u201330.","journal-title":"N Engl J Med"},{"key":"3126_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1474-4422(16)30395-7","volume":"16","author":"The Lancet Neurology","year":"2017","unstructured":"The Lancet Neurology. Solanezumab: too late in mild Alzheimer\u2019s disease? Lancet Neurol. 2017;16:97.","journal-title":"Lancet Neurol"},{"key":"3126_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37.","journal-title":"Alzheimers Res Ther"},{"key":"3126_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/00207454.2013.833510","volume":"124","author":"Z Cai","year":"2014","unstructured":"Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer\u2019s disease. Int J Neurosci. 2014;124:307\u201321.","journal-title":"Int J Neurosci"},{"key":"3126_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/JAD-2010-1219","volume":"19","author":"EG McGeer","year":"2010","unstructured":"McGeer EG, McGeer PL. Neuroinflammation in Alzheimer\u2019s disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis. 2010;19:355\u201361.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"3126_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1083\/jcb.201709069","volume":"217","author":"DV Hansen","year":"2018","unstructured":"Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer\u2019s disease. J Cell Biol. 2018;217(2):459\u201372.","journal-title":"J Cell Biol"},{"key":"3126_CR19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1021\/acsptsci.0c00073","volume":"3","author":"P Sun","year":"2020","unstructured":"Sun P, Yue H, Xing Q, et al. Compound AD16 reduces amyloid plaque deposition and modifies microglia in a transgenic mouse model of Alzheimer\u2019s disease. ACS Pharmacol Transl Sci. 2020;3:1100\u201310.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3126_CR20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1021\/acschemneuro.6b00125","volume":"7","author":"W Zhou","year":"2016","unstructured":"Zhou W, Zhong G, Fu S, et al. Microglia-based phenotypic screening identifies a novel inhibitor of neuroinflammation effective in Alzheimer\u2019s disease models. ACS Chem Neurosci. 2016;7:1499\u2013507.","journal-title":"ACS Chem Neurosci"},{"key":"3126_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s12264-021-00816-3","volume":"38","author":"Z Huang","year":"2022","unstructured":"Huang Z, Luo Z, Ovcjak A, et al. AD-16 protects against hypoxic-ischemic brain injury by inhibiting neuroinflammation. Neurosci Bull. 2022;38:857\u201370.","journal-title":"Neurosci Bull"},{"key":"3126_CR22","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32.","DOI":"10.1186\/1745-6215-11-32"},{"key":"3126_CR23","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1042\/BST0351122","volume":"35","author":"A Simi","year":"2007","unstructured":"Simi A, Tsakiri N, Wang P, Rothwell NJ. Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans. 2007;35:1122\u20136.","journal-title":"Biochem Soc Trans"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03126-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-03126-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03126-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T10:08:04Z","timestamp":1700734084000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-03126-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3126"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-03126-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guideline. Study protocols and all amendments were approved by the Medical Ethics Committee of Xiangya Hospital Central South University (approval numbers: 201812122\/201904103\/201812122\u20132, 202004089, 201908150). All subjects provided written informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yahui Wang is an employee of the South China Center for Innovative Pharmaceuticals, which sponsored this study. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"459"}}